Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUV-1511 in advanced solid tumors
NCT06334432Phase 2Active, not recruiting
- Sponsor
- Nuvation Bio
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ARTS-021 in breast cancer, metastatic castration-resistant prostate cancer (mCRPC), pancreatic cancer (PC), ovarian cancer, sponsored by Nuvation Bio. Started Mar 2024; status: active, not recruiting.
02
Drugs
ARTS-021
03
Conditions
breast cancermetastatic castration-resistant prostate cancer (mCRPC)pancreatic cancer (PC)ovarian cancer
Beyond the preview
Go deeper on NCT06334432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06334432.